📊 BOLT Key Takeaways
Is Bolt Biotherapeutics, Inc. (BOLT) a Good Investment?
Bolt Biotherapeutics is a pre-revenue stage biopharmaceutical company burning significant cash with minimal revenue generation and no clear path to profitability in the near term. The company is consuming cash at an unsustainable rate with only 11.7M in cash against 39.9M annual operating cash burn, providing approximately 3-4 quarters of runway at current burn rates. Absent major clinical trial successes or financing, the company faces severe liquidity constraints that threaten its continued operations.
Bolt Biotherapeutics shows very weak fundamentals, with minimal revenue growth, deeply negative operating and net margins, and substantial ongoing cash burn. While the balance sheet has no meaningful debt and short-term liquidity ratios appear solid, the current cash position looks thin relative to annual operating outflows, making funding risk a central concern. Growth quality is poor because revenue has not scaled enough to offset R&D and operating costs.
Why Buy Bolt Biotherapeutics, Inc. Stock? BOLT Key Strengths
- Strong liquidity position with 3.59x current ratio and quick ratio, indicating ability to meet short-term obligations
- Minimal leverage with 0.00x debt-to-equity ratio, preserving financial flexibility for future financing
- Reduced operating losses year-over-year with diluted EPS improving 46% (though still deeply negative at -17.85)
- Debt-free balance sheet reduces financial leverage risk
- Current and quick ratios of 3.59x indicate adequate near-term balance sheet liquidity
- Positive reported revenue base provides some non-zero operating inflow
BOLT Stock Risks: Bolt Biotherapeutics, Inc. Investment Risks
- Severe cash burn of 39.9M annually against only 11.7M cash reserves, providing critical runway of less than 4 quarters
- Astronomical negative margins with -469.3% operating margin and -433.7% net margin indicating fundamental business model challenges
- Revenue of only 7.7M is inadequate to support R&D-heavy biopharmaceutical operations, with no gross margin visibility suggesting revenue may be contract or milestone-based rather than product sales
- Negative free cash flow of -39.9M and total losses exceeding 33M annually demonstrate unsustainable burn rate
- No long-term debt data available and minimal insider activity (3 Form 4 filings in 90 days) may indicate limited confidence from insiders
- Operating loss of $36.11M on just $7.70M of revenue reflects an unsustainable cost structure
- Free cash flow of -$39.92M versus $11.70M of cash suggests limited runway without additional capital
- Flat revenue growth indicates weak commercial traction or limited monetization progress
Key Metrics to Watch
- Operating cash burn rate and cash runway until liquidity crisis
- Clinical trial progress and FDA milestone achievements that could unlock revenue or financing
- Quarterly revenue trends and whether any pipeline programs are generating meaningful revenue
- Capital raise announcements or debt restructuring given critical runway constraints
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and operating loss improvement
Bolt Biotherapeutics, Inc. (BOLT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.59x current ratio provides a solid financial cushion.
BOLT Profit Margin, ROE & Profitability Analysis
BOLT vs Healthcare Sector: How Bolt Biotherapeutics, Inc. Compares
How Bolt Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bolt Biotherapeutics, Inc. Stock Overvalued? BOLT Valuation Analysis 2026
Based on fundamental analysis, Bolt Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bolt Biotherapeutics, Inc. Balance Sheet: BOLT Debt, Cash & Liquidity
BOLT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bolt Biotherapeutics, Inc.'s revenue has grown significantly by 511% over the 5-year period, indicating strong business expansion. The most recent EPS of $-33.06 indicates the company is currently unprofitable.
BOLT Revenue Growth, EPS Growth & YoY Performance
BOLT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$7.1M | $-3.72 |
| Q2 2025 | $1.3M | -$8.6M | $-4.46 |
| Q1 2025 | $1.2M | -$10.8M | $-0.28 |
| Q3 2024 | $1.1M | -$15.2M | $-0.40 |
| Q2 2024 | $1.3M | -$18.1M | $-0.48 |
| Q1 2024 | $1.8M | -$10.8M | $-0.28 |
| Q3 2023 | $2.1M | -$16.3M | $-0.43 |
| Q2 2023 | $1.4M | -$18.1M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bolt Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
BOLT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLT
What is the AI rating for BOLT?
Bolt Biotherapeutics, Inc. (BOLT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLT's key strengths?
Claude: Strong liquidity position with 3.59x current ratio and quick ratio, indicating ability to meet short-term obligations. Minimal leverage with 0.00x debt-to-equity ratio, preserving financial flexibility for future financing. ChatGPT: Debt-free balance sheet reduces financial leverage risk. Current and quick ratios of 3.59x indicate adequate near-term balance sheet liquidity.
What are the risks of investing in BOLT?
Claude: Severe cash burn of 39.9M annually against only 11.7M cash reserves, providing critical runway of less than 4 quarters. Astronomical negative margins with -469.3% operating margin and -433.7% net margin indicating fundamental business model challenges. ChatGPT: Operating loss of $36.11M on just $7.70M of revenue reflects an unsustainable cost structure. Free cash flow of -$39.92M versus $11.70M of cash suggests limited runway without additional capital.
What is BOLT's revenue and growth?
Bolt Biotherapeutics, Inc. reported revenue of $7.7M.
Does BOLT pay dividends?
Bolt Biotherapeutics, Inc. does not currently pay dividends.
Where can I find BOLT SEC filings?
Official SEC filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLT's EPS?
Bolt Biotherapeutics, Inc. has a diluted EPS of $-17.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BOLT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bolt Biotherapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BOLT stock overvalued or undervalued?
Valuation metrics for BOLT: ROE of -125.9% (sector avg: 15%), net margin of -433.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BOLT stock in 2026?
Our dual AI analysis gives Bolt Biotherapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BOLT's free cash flow?
Bolt Biotherapeutics, Inc.'s operating cash flow is $-39.9M, with capital expenditures of $72.0K. FCF margin is -518.8%.
How does BOLT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -433.7% (avg: 12%), ROE -125.9% (avg: 15%), current ratio 3.59 (avg: 2).